MacroGenics, Inc. (NASDAQ:MGNX – Get Free Report) major shareholder Target N. V. Biotech bought 200,000 shares of the business’s stock in a transaction that occurred on Thursday, September 7th. The shares were acquired at an average price of $5.26 per share, with a total value of $1,052,000.00. Following the completion of the transaction, the insider […]
MacroGenics, Inc. (NASDAQ:MGNX – Get Free Report) major shareholder Target N. V. Biotech purchased 200,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 7th. The stock was purchased at an average price of $5.26 per share, with a total value of $1,052,000.00. Following the completion of the purchase, the insider […]
StockNews.com upgraded shares of MacroGenics (NASDAQ:MGNX – Free Report) from a hold rating to a buy rating in a report released on Friday. Several other equities analysts have also recently commented on the stock. JMP Securities boosted their price objective on shares of MacroGenics from $8.00 to $10.00 in a research note on Thursday, May […]
StockNews.com began coverage on shares of MacroGenics (NASDAQ:MGNX – Free Report) in a research note released on Thursday. The brokerage issued a hold rating on the biopharmaceutical company’s stock. A number of other equities research analysts have also issued reports on MGNX. JMP Securities increased their price target on MacroGenics from $8.00 to $10.00 in […]
StockNews.com started coverage on shares of MacroGenics (NASDAQ:MGNX – Free Report) in a research note published on Thursday. The firm issued a hold rating on the biopharmaceutical company’s stock. Several other equities research analysts also recently issued reports on MGNX. HC Wainwright reiterated a buy rating and set a $14.00 price objective on shares of […]